<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239706</url>
  </required_header>
  <id_info>
    <org_study_id>23036</org_study_id>
    <nct_id>NCT01239706</nct_id>
  </id_info>
  <brief_title>Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1</brief_title>
  <official_title>A Phase IIa, Single Centre, Open Label Study to Characterize the Safety of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stem Cell Therapeutics Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Open Label, Cohort Study in Traumatic Brain Injury Patients. The goal of this&#xD;
      study is to assess the safety of NTx®-265. NTx®-265 will be administered over 9 days, and&#xD;
      patients will be followed for an additional 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint for this study is safety. The following safety endpoints will be assessed:&#xD;
Type, incidence, severity, timing, seriousness, and relatedness of adverse events.&#xD;
Lower extremity deep vein ultrasound will be performed to identify and localize deep or superficial venous thrombosis.&#xD;
Vital signs&#xD;
Laboratory assessments. Particular attention will be paid to serial hemoglobin and hematocrit measurements.&#xD;
DVT, PE, thromboembolism, MI and stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>The following secondary endpoints will also be assessed in order to measure various aspects of neurological status:&#xD;
GOSE at hospital discharge, 3, and 6 months post-TBI&#xD;
Neurobehavioral Rating Score at hospital discharge, 3, and 6 months post TBI&#xD;
Disability Rating Score at hospital discharge, 3, and 6 months post TBI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>NTx 265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTx 265</intervention_name>
    <description>10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin</description>
    <arm_group_label>NTx 265</arm_group_label>
    <other_name>Eprex, Ortho Biotech</other_name>
    <other_name>Ovidrel, Serono</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients age 18-65&#xD;
&#xD;
          2. Written and informed consent from a legally acceptable representative&#xD;
&#xD;
          3. Moderate to severe traumatic brain injury (TBI) defined as Glasgow Coma motor (GCSm)&#xD;
             score ≤5, post resuscitation.&#xD;
&#xD;
          4. Patient is &lt;48hours from time of injury when the first dose of NTx™-265 is&#xD;
             administered.&#xD;
&#xD;
          5. Reasonable expectation of availability to receive the full 9 day course of therapy and&#xD;
             be available for follow up evaluations&#xD;
&#xD;
          6. Female patient is either:&#xD;
&#xD;
               1. Not of childbearing potential, defined as postmenopausal for at least 1 year or&#xD;
                  surgically sterile (bilateral oophorectomy or hysterectomy) or&#xD;
&#xD;
               2. If of childbearing potential, would agree to use two of the following reliable&#xD;
                  methods of birth control throughout the study, including the follow-up visits:&#xD;
&#xD;
                    -  Condoms, sponge, foams, jellies, diaphragm or intrauterine device&#xD;
&#xD;
                    -  A vasectomised partner&#xD;
&#xD;
                    -  Abstinence&#xD;
&#xD;
                    -  Note: Hormonal Based contraceptives are NOT permissible as one of the two&#xD;
                       forms of contraceptives for this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who have been tested positive for pregnancy, or are breast-feeding or are not&#xD;
             using a highly effective method of birth control that can be maintained for the&#xD;
             duration of the study.&#xD;
&#xD;
          2. Bilaterally fixed pupils&#xD;
&#xD;
          3. Serum hemoglobin &gt;160g/L (males) or &gt;140g/L (female); or platelet count &gt; 400,000/mm3&#xD;
&#xD;
          4. Advanced cardiac, pulmonary, hepatic or liver disease; the former will be&#xD;
             operationally defined using NCI Toxicity Criteria (Grade 2 or higher).&#xD;
&#xD;
          5. Suspected anoxic or ischemic brain injury&#xD;
&#xD;
          6. Known endocrine or germ cell tumor&#xD;
&#xD;
          7. Serum billirubin &gt; 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
          8. Alkaline Phosphatase &gt; 2.5 x ULN&#xD;
&#xD;
          9. AST and/or ALT &gt; 2.5 x ULN&#xD;
&#xD;
         10. Creatinine &gt; 2.0 x ULN&#xD;
&#xD;
         11. Patients with known or documented transferrin saturation &lt; 20% or ferritin &lt; 100ng/mL.&#xD;
&#xD;
         12. Male patients with known and documented elevated PSA levels, or a PSA level of ≥4ng/mL&#xD;
             at screening.&#xD;
&#xD;
         13. Patients with known history or hypercoagulability, including known&#xD;
             cardiolipin/antiphospholipid antibody syndrome.&#xD;
&#xD;
         14. Allergy or other contraindication to hCG including:&#xD;
&#xD;
               1. Prior hypersensitivity to hCG preparations or one of their excipients.&#xD;
&#xD;
               2. Primary ovarian failure.&#xD;
&#xD;
               3. Uncontrolled thyroid or adrenal dysfunction.&#xD;
&#xD;
               4. An uncontrolled organic intracranial lesion such as a pituitary tumor.&#xD;
&#xD;
               5. Abnormal uterine bleeding of undetermined origin.&#xD;
&#xD;
               6. Ovarian cyst or ovarian enlargement of undetermined origin.&#xD;
&#xD;
               7. Sex hormone dependent tumors of the reproductive organs, accessory sex glands,&#xD;
                  and breasts.&#xD;
&#xD;
         15. Allergy or other contraindication to epoetin alfa:&#xD;
&#xD;
               1. Who developed pure red cell aplasia following treatment with any erythropoiesis&#xD;
                  regulating hormones.&#xD;
&#xD;
               2. With uncontrolled hypertension&#xD;
&#xD;
               3. With known hypersensitivity to mammalian cell-derived products, albumin (human)&#xD;
                  or any component of the product&#xD;
&#xD;
               4. Who for any reason cannot receive adequate antithrombotic treatment&#xD;
&#xD;
         16. A known diagnosis of cancer (except basal cell cancer).&#xD;
&#xD;
         17. Uncontrolled hypertension, defined as blood pressure persistently above 220 mm Hg&#xD;
             systolic or 120 mm Hg diastolic despite antihypertensive therapy.&#xD;
&#xD;
         18. Use of either hCG or epoetin alfa within the previous 90 days.&#xD;
&#xD;
         19. Any condition known to elevate hCG, active in the prior 24 months e.g.,&#xD;
             choriocarcinoma or germ cell tumor.&#xD;
&#xD;
         20. Any patients living in a nursing home or supervised living center. Patients must be&#xD;
             historically fully independent in all activities of daily living including banking,&#xD;
             shopping, cooking, toileting, showering and dressing.&#xD;
&#xD;
         21. Any other medical condition, in the investigator's opinion, the patient should not be&#xD;
             included in the trial.&#xD;
&#xD;
         22. Patients who cannot take anti-platelet or anti-coagulant therapy.&#xD;
&#xD;
         23. Pre-existing and active major psychiatric or other chronic Neurological disease.&#xD;
&#xD;
         24. Patients who have a history of substance abuse or dependency within 12 months prior to&#xD;
             the study.&#xD;
&#xD;
         25. Currently participating in another investigational study&#xD;
&#xD;
         26. Polytrauma defined as an Abbreviated Injury Severity Score &gt;3 in any area other than&#xD;
             head.&#xD;
&#xD;
         27. Patients with evidence of an active or previous thrombotic event.&#xD;
&#xD;
         28. Patients with contraindications to MRI scans&#xD;
&#xD;
         29. Patients who are currently taking hormonal based contraceptives or hormonal&#xD;
             replacement therapy in the past three (3) months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Zygun, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Zygun, MD</last_name>
    <phone>403-944-1691</phone>
    <email>dzygun@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Todd, BSc, MBT, CCRP</last_name>
    <phone>403-944-3414</phone>
    <email>stephanie.todd@albertahealthservices.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Todd, BSc, MBT, CCRP</last_name>
      <phone>403-944-3414</phone>
      <email>stephanie.todd@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>David A Zygun, MD, MSc,</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Kramer, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clare Gallagher, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Scott, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>November 10, 2010</last_update_submitted>
  <last_update_submitted_qc>November 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. David A Zygun</name_title>
    <organization>University of Calgary</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

